NCT02678182 - Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial | Biotech Hunter

Enrollment

494

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

April 17, 2025

Study Completion Date

June 30, 2027

Conditions

Adenocarcinoma of the OesophagusAdenocarcinoma of the Gastro-oesophageal JunctionAdenocarcinoma of the Stomach

Interventions

DRUG

Capecitabine

1250 mg/m2/day, 21 day cycle

DRUG

MEDI4736 (Durvalumab)

IV treatment on days 1\&15 of 28 day cycle

DRUG

Trastuzumab

6mg/kg on day 1 cycle every 21 days

DRUG

Rucaparib

600mg PO twice daily

DRUG

Ramucirumab

ramucirumab 8mg/kg IV day 1 and day 8

Trial Locations (1)

The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Sutton